首页> 外文期刊>BMJ Open Quality >Increasing contraception use among women receiving teratogenic medications in a rheumatology clinic
【24h】

Increasing contraception use among women receiving teratogenic medications in a rheumatology clinic

机译:在风湿病诊所接受致畸药物的妇女避孕药具的使用增加

获取原文
           

摘要

Teratogenic medications are often prescribed to women of childbearing age with autoimmune diseases. Literature suggests that appropriate use of contraception among these women is low, potentially resulting in high-risk unintended pregnancies. Preliminary review in our clinic showed suboptimal documentation of women’s contraceptive use. We therefore designed a quality improvement initiative to target three process measures: documentation of contraception usage and type, contraception counselling and provider action after counselling. We reviewed charts of rheumatology clinic female patients aged 18–45 over the course of 10 months; for those who were on teratogenic medications (methotrexate, leflunomide, mycophenolate and cyclophosphamide), we looked for evidence of documentation of contraception use. We executed multiple plan-do-study-act (PDSA) cycles to develop and evaluate interventions, which centred on interprofessional provider education, modification of electronic medical record (EMR) templates, periodic provider reminders, patient screening questionnaires and frequent feedback to providers on performance. Among eligible patients (n=181), the baseline rate of documentation of contraception type was 46%, the rate of counselling was 30% and interventions after counselling occurred in 33% of cases. Averaged intervention data demonstrated increased provider performance in all three domains: documentation of contraception type increased to 64%, counselling to 45% and provider action to 46%. Of the patients with documented contraceptives, 50% used highly effective, 27% used effective and 23% used ineffective contraception methods. During this project, one unintentional pregnancy occurred in a patient on methotrexate not on contraception. Our interventions improved three measures related to contraception counselling and documentation, but there remains a need for ongoing quality improvement efforts in our clinic. This high-risk population requires increased provider engagement to improve contraception compliance, coupled with system-wide EMR changes to increase sustainability.
机译:致畸胎的药物通常开给具有自身免疫性疾病的育龄妇女。文献表明,在这些妇女中适当使用避孕药具的可能性很低,可能导致意外怀孕的高风险。我们诊所的初步审查显示,妇女使用避孕药具的文献不尽人意。因此,我们设计了一项质量改进计划,以三个过程指标为目标:避孕用法和类型的文件记录,避孕咨询以及咨询后的提供者行动。我们回顾了10个月内18-45岁的风湿病临床女性患者的图表;对于那些正在使用致畸药物(甲氨蝶呤,来氟米特,霉酚酸酯和环磷酰胺)的人,我们寻找了使用避孕药具的证据。我们执行了多个计划研究行为(PDSA)周期来开发和评估干预措施,这些干预措施集中于专业人员之间的提供者教育,电子病历(EMR)模板的修改,提供者的定期提醒,患者筛查问卷以及对提供者的频繁反馈性能。在符合条件的患者中(n = 181),避孕类型文献的基线记录率为46%,咨询率为30%,咨询后进行干预的病例为33%。平均干预数据表明,在所有三个领域中,提供者的绩效均得到提高:避孕类型的文件记录增加至64%,咨询服务增加到45%,提供者采取的行动增加到46%。在有记录的避孕方法的患者中,50%使用了有效避孕方法,27%使用了有效避孕方法,23%使用了无效避孕方法。在该项目期间,一名接受甲氨蝶呤而非避孕药的患者意外怀孕。我们的干预措施改进了与避孕咨询和文件记录有关的三项措施,但仍然需要在我们的诊所中不断进行质量改进工作。这种高风险人群需要更多的医疗服务提供者参与以改善避孕的依从性,并需要对全系统的EMR进行更改以提高可持续性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号